BidaskClub downgraded shares of Meridian Bioscience Inc. (NASDAQ:VIVO) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday morning.

Several other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Meridian Bioscience from a hold rating to a sell rating in a report on Thursday, July 13th. Canaccord Genuity boosted their price target on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a hold rating in a report on Wednesday, May 3rd. Three analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $14.75.

Meridian Bioscience (VIVO) traded up 0.74% during mid-day trading on Wednesday, hitting $13.70. 145,971 shares of the stock traded hands. Meridian Bioscience has a 1-year low of $10.75 and a 1-year high of $19.85. The firm has a market cap of $578.17 million, a price-to-earnings ratio of 27.40 and a beta of 0.89. The stock has a 50-day moving average of $15.21 and a 200 day moving average of $14.12.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The company had revenue of $50.14 million during the quarter, compared to the consensus estimate of $49.13 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. The company’s revenue for the quarter was down 1.0% compared to the same quarter last year. On average, equities analysts expect that Meridian Bioscience will post $0.67 EPS for the current year.

WARNING: This news story was first reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/05/meridian-bioscience-inc-vivo-downgraded-by-bidaskclub.html.

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 17th. Stockholders of record on Monday, August 7th will be issued a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, August 3rd. Meridian Bioscience’s dividend payout ratio (DPR) is 98.04%.

A number of large investors have recently bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Meridian Bioscience during the first quarter worth approximately $105,000. BNP Paribas Arbitrage SA increased its position in shares of Meridian Bioscience by 12.5% in the first quarter. BNP Paribas Arbitrage SA now owns 8,633 shares of the company’s stock worth $119,000 after buying an additional 960 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of Meridian Bioscience by 77.5% in the second quarter. State of Alaska Department of Revenue now owns 8,273 shares of the company’s stock worth $130,000 after buying an additional 3,613 shares during the last quarter. Mason Street Advisors LLC increased its position in shares of Meridian Bioscience by 7.2% in the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock worth $136,000 after buying an additional 667 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its position in shares of Meridian Bioscience by 3.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock worth $157,000 after buying an additional 370 shares during the last quarter. 85.87% of the stock is owned by institutional investors and hedge funds.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.